Blueprint Medicines Stock Target Price and Analyst Consensus
| BPMC Stock | USD 92.26 0.03 0.03% |
The current analyst and expert consensus on Blueprint Medicines is Buy, with 1 strong sell and 8 strong buy opinions. The current projected Blueprint Medicines target price consensus is 74.65 with 17 analyst opinions. The most common way Blueprint Medicines Corp analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview Blueprint Medicines executives and customers to further validate their buy or sell advice. Blueprint Medicines buy-or-sell recommendation module provides average expert sentiment on the projected Blueprint Medicines Corp target price to derive its highest and lowest estimates based on its projected price volatility. Check out Macroaxis Advice on Blueprint Medicines to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon.
Lowest Forecast 67.93 | Highest Forecast 82.86 | Target Price 74.65 |
Blueprint |
It's important to approach Blueprint Medicines' target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.
Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.
Steps to utilize Blueprint Medicines price targets
Blueprint Medicines' stock target price is an estimate of its future price, usually made by analysts. Using Blueprint Medicines' target price to determine if it is a suitable investment can be done through the following steps:- Look at Blueprint Medicines' target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
- Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
- Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
- Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if Blueprint Medicines' stock is likely to perform well.
- Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Additional Blueprint Medicines Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Blueprint Medicines is a key component of Blueprint Medicines valuation and have some predictive power on the future returns of a Blueprint Medicines.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Blueprint Medicines' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Business Services Invested over 100 shares | |
 | Hedge Favorites Invested over 60 shares | |
 | Macroaxis Index Invested few shares | |
 | Baby Boomer Prospects Invested over 40 shares | |
Check out Macroaxis Advice on Blueprint Medicines to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Complementary Tools for Blueprint Stock analysis
When running Blueprint Medicines' price analysis, check to measure Blueprint Medicines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Blueprint Medicines is operating at the current time. Most of Blueprint Medicines' value examination focuses on studying past and present price action to predict the probability of Blueprint Medicines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Blueprint Medicines' price. Additionally, you may evaluate how the addition of Blueprint Medicines to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |
The data published in Blueprint Medicines' official financial statements usually reflect Blueprint Medicines' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Blueprint Medicines Corp. For example, before you start analyzing numbers published by Blueprint accountants, it's critical to develop an understanding of what Blueprint Medicines' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Blueprint Medicines' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Blueprint Medicines' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Blueprint Medicines' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Blueprint Medicines Corp. Please utilize our Beneish M Score to check the likelihood of Blueprint Medicines' management manipulating its earnings.